Loading
Adding ifosfamide and etoposide improved cure rates for localised Ewing sarcoma, setting the backbone still used today.
INT-0091, trial NCT00002516 run by the Children's Cancer Group and the Pediatric Oncology Group and published in the New England Journal of Medicine in 2003, showed that adding ifosfamide and etoposide to vincristine, doxorubicin and cyclophosphamide improved cure rates in localised Ewing sarcoma, setting the backbone still used today. It randomised 518 patients and improved event-free survival at five years in non-metastatic disease, with no benefit in metastatic disease. OnCo links it to sarcomas, doxorubicin, ifosfamide and the Children's Oncology Group. It is the foundation of VDC/IE, which interval compression in AEWS0031 later improved, and why the same drugs fail in metastatic disease is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Ifosfamide, Children's Oncology Group (COG), Doxorubicin, Sarcomas (soft tissue, bone, GIST).
Shares Ifosfamide, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Cytotoxic chemotherapy.
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Sarcomas (soft tissue, bone, GIST).
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Sarcomas (soft tissue, bone, GIST).
Shares Children's Oncology Group (COG), Doxorubicin, Cytotoxic chemotherapy.
Shares Ifosfamide, Doxorubicin, Cytotoxic chemotherapy.
Shares Ifosfamide, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Children's Oncology Group (COG), Doxorubicin.
Shares Ifosfamide, Doxorubicin, Sarcomas (soft tissue, bone, GIST), Cytotoxic chemotherapy.